Short answer
Vertex Pharmaceuticals (VRTX) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 and first-half 2026 consolidated results reported for periods ended June 30, 2026.
Vertex Pharmaceuticals 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 and first-half 2026 consolidated results reported for periods ended June 30, 2026
- Press release attached as Exhibit 99.1, containing detailed financial results and management commentary
- Results disclosed under Item 2.02, but exhibit excluded from Section 18 filing liability and registration-statement incorporation by default
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $3.33B, up 12%; GAAP net income $1.10B, up from $1.03B, supporting continued earnings momentum
- FY2026 revenue guidance raised to $13.1B–$13.2B from $12.95B–$13.1B, signaling stronger commercial execution
- ALYFTREK revenue $573.6M versus $156.8M; CASGEVY $76.4M and JOURNAVX $49.6M reinforce portfolio diversification
- Crinetics acquisition agreed at $85 per share, approximately $10.0B equity value, with closing expected in Q3 2026
- Povetacicept PDUFA date November 30, 2026; approval could establish Vertex’s first commercial nephrology product
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vertex Pharmaceuticals 8-K filings
Get the next VRTX 8-K as it lands
Follow VRTX for push alerts, or ask the research agent what this filing means.